Drug news: CF-101 trial enrollment complete
Can-Fite completes recruitment for dry-eye trial
Can-Fite BioPharma Ltd. (TASE:CFBI) has completed recruitment for the Phase II clinical trial of its CF-101 drug for the treatment of dry-eye syndrome (keratoconjunctivitis sicca). 80 patients will participate in the trial at six Israeli medical centers. Patients will take the drug over twelve weeks and monitored for two more weeks.
Can-Fite expects to publish the results of the trial during the second quarter of 2009.